€ 8192 m
Q3/2017: €7,927 m1
€ 1463 m
Q3/2017: €1,481 m
€ 1112 m
Q3/2017: €1,129 m
Dec. 31, 2017: 273,249
€ 445 m
Q3/2017: €413 m
Earnings per Share3
1 Adjusted for IFRS 15 adoption and divestitures of Care Coordination activities
2 In constant currency
3 Before special items
4 Before divestitures of Care Coordination activities
Stephan Sturm, Chairman of the Management Board
Omegaven® is an intravenous lipid emulsion that provides calories and fatty acids. In the U.S. it is indicated for pediatric patients with parenteral nutrition-associated cholestasis, or PNAC. With Omegaven® Fresenius Kabi provides the first and only FDA-approved fish oil lipid emulsion for this condition.
The Supervisory Board of Fresenius SE & Co. KGaA has decided to propose PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft as the auditor for the financial year 2020. The shareholders will decide on the appointment at the Annual General Meeting in 2020. New regulations provide for a regular rotation of the auditor, so Fresenius was not able to extend the existing mandate of KPMG AG Wirtschaftsprüfungsgesellschaft.
Fresenius Kabi has received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration (FDA). The FDA recognized the role Fresenius Kabi played in helping mitigate a shortage of IV saline, specifically Sodium Chloride Injection USP, 0.9% in bags. The shortage was caused last year by supply disruptions at manufacturers affected by Hurricane Maria. The hurricane devastated Puerto Rico, where many companies produce medicines for U.S. hospitals.
VAMED Vitality World has been named the “World’s Best Thermal Spa & Medical Wellness Operator 2018” at the World Spa Awards. Four VAMED Vitality World facilities – Geinberg5 Private Villas, Aqua Dome Therme Längenfeld, Therme Laa Hotel & Spa, all in Austria, and Aquaworld Resort Budapest in the Hungarian capital – also won in their individual categories. VAMED Vitality World, part of Fresenius Vamed, operates a total of nine spa and health resorts in Austria and Hungary.
A recent study places Fresenius among the top 500 companies in terms of career training programs in Germany. Criteria used for judgement were the quality of supervision, in-house training, company engagement, success rate and innovative teaching methods. The companies were rated by the business magazine Capital and the internet portal, ausbildung.de. Fresenius received a best possible five-star rating for its on-the-job training and dual-studies, a combination of theory and on-the-job training, programs. The company trains more than 4,000 apprentices and dual-studies interns.
Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, has acquired Clínica Medellín and entered the attractive private hospital market in Colombia. Clínica Medellín operates two centrally located hospitals in Medellín, a major city of 2.5 million people. The two facilities have a total of about 185 beds. The total investment for Clínica Medellín is more than €50 million. Following Quirónsalud's entry into Peru last year, this is another step in strengthening the company’s presence in Latin America’s growing and consolidating hospital markets. Fresenius Helios expects the transaction to close in Q1 2019, pending anti-trust and regulatory clearance.
Arsenic Trioxide Injection is the newest addition to the company’s oncology portfolio.
Fresenius Kabi HYDROmorphone Hydrochloride injection is a new offering for the company, expanding its analgesia and anesthesia portfolio. It is available in six single-dose vial presentations.
Palonosetron Hydrochloride Injection is now available in the U.S. and is the newest product in the company’s Simplist™ prefilled syringe portfolio. It is an antiemetic used to manage chemotherapy-induced nausea and vomiting. Fresenius Kabi is the first company to offer U.S. customers Palonosetron Hydrochloride in a ready-to-administer syringe.
Fresenius Kabi has launched Heparin Sodium injection in ready-to-administer non-DEHP freeflex® bags, expanding the company’s critical care portfolio. Fresenius Kabi offers a comprehensive portfolio of Heparin Sodium in the U.S. with multiple vial presentations, a pre-filled syringe and bag presentations.
Fresenius Kabi has opened a new state-of-the-art compounding center in Canada. It involves an investment of 11 million Canadian dollars (more than €7 million), and the new site expands the company’s presence in Mississauga, Ontario. Fresenius Kabi is responding to increasing demand for large batches of compounded medications for patients in Canadian hospitals, and the 35,000-square-foot (3,300-square-meter) compounding center has the capacity to expand. The new facility is expected to employ 70 people by 2022.
Fresenius Kabi has reached a milestone on the road to approval for another biosimilar. MSB11455, a biosimilar candidate for Neulasta® (pegfilgrastim), has met its primary endpoints in the two pivotal clinical studies. For more information please see the website of Fresenius Kabi.
The price increase for hospital services in Germany has been set at 2.65% for 2019. This is in line with the level of past years.
Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, is opening a new hospital in Cordoba today. The company now has six hospitals in Andalusia, Spain’s most southernly autonomous community. The six-floor, approximately 25,000-square-meter (269,000-square-foot) facility includes 100 large private patient rooms, a 24-hour emergency department, seven operating rooms and a surgical outpatient clinic. Quirónsalud has invested €50 million in the new hospital.
Fresenius Helios has opened a new emergency unit at Helios Hospital Leisnig, in the eastern German state of Saxony. It contains four modern examination rooms and a specially equipped reanimation room, which will enable the hospital to provide even better care for its emergency patients, who now number some 10,000 annually. Architecturally optimized for medical processes and procedures, the new emergency unit was built in only 12 months. It required an investment by Fresenius Helios of about €1 million.
Atropine Sulfate Injection further expands the company's anesthesia and analgesia portfolio.
Glycopyrrolate Injection is the newest addition to the company’s anesthesia and analgesia portfolio.
Fresenius Helios will take responsibility for practical instruction as part of the first worldwide digitalized medical studies program. The new course of study meets European certification standards and will start in the winter semester 2018/2019 at the EDU College of Medicine, Malta. Theoretical components of a bachelor’s and follow-on master’s program will be available solely via an online platform. Students will be networked into learning communities taught by faculty. About one-third of the course is practical instruction that will take place in hospitals operated by Fresenius Helios in Germany. The program initially will be limited to 75 students. The long-term goal is up to 3,000 students.
Fresenius Kabi is expanding its production and warehouse capacity in Runcorn, England, to meet increasing demand in United Kingdom’s homecare market and from UK and Ireland hospitals. The expansion’s first stage will be a new distribution and operations center, scheduled to open in early 2019. A second services unit for producing aseptically compounded parenteral nutrition products will be completed by 2020. Fresenius Kabi will invest over €9 million in the expansion.
Jiménez Díaz Foundation University Hospital in Madrid has again been awarded the EFQM Recognized for Excellence award with the maximum five stars, this time also receiving the highest rating of any hospital in Spain. The 667-bed facility earned more than 650 points on the rating scale used by the European Foundation for Quality Management during a comprehensive management and process evaluation earlier this year. In the award presentation, the EFQM cited Jiménez Díaz Foundation University Hospital’s intensive focus on patient care, as well as its continuous improvements in treatments and the use of medical technology. This leading teaching hospital is part of the Quirónsalud group, the Spanish unit of Fresenius Helios.
Melphalan Hydrochloride for Injection is the newest addition to the company’s oncology portfolio.
Fresenius Factsheet Q3/2018 (PDF, 469 KB)
Quarterly Financial Report Q3 2018 (IFRS) (PDF, 423 KB)
Investor Relations General Presentation (PDF, 1.54 MB)
Quarterly Financial Report Q2 2018 (IFRS) (PDF, 387 KB)
Quarterly Financial Report Q1 2018 (IFRS) (PDF, 334 KB)
Annual Report 2017 (IFRS) (PDF, 3.21 MB)
Quarterly Financial Report Q3 2017 (IFRS) (PDF, 350 KB)
Quarterly Financial Report Q2 2017 (IFRS) (PDF, 380 KB)
Quarterly Financial Report Q1 2017 (IFRS) (PDF, 295 KB)
Annual Report 2016 (U.S. GAAP) (PDF, 2.89 MB)
Consolidated Financial Statements / Management Report 2016 (IFRS) (PDF, 1.02 MB)
Quarterly Financial Report Q3 2016 (US-GAAP) (PDF, 337 KB)
Quarterly Financial Report Q3 2016 (IFRS) (PDF, 373 KB)
Quarterly Financial Report Q2 2016 (US-GAAP) (PDF, 369 KB)
Quarterly Financial Report Q2 2016 (IFRS) (PDF, 333 KB)
Quarterly Financial Report Q1 2016 (US-GAAP) (PDF, 830 KB)
Quarterly Financial Report Q1 2016 (IFRS) (PDF, 309 KB)
Annual Report 2015 (US-GAAP) (PDF, 3.18 MB)
Consolidated Financial Statements / Management Report 2015 (IFRS) (PDF, 1.02 MB)